$249.00
Pharmacy benefit managers (PBMs) play a major role in the provision of pharmacy services by acting as intermediaries. As the role of and visibility have increased, PBMs have come under increased scrutiny from policy makers for their role in drug pricing discussions.
The 2024-2025 PBM Review (210 pages) offers comprehensive intelligence on nearly 70 PBM companies.
The report identifies and segments the market into Market Leaders, Mid-Market PBMs, and Non-Traditional PBMs.
Each PBM company profile includes: company background, strategy, key decision-makers, financial/investor information, products and services, and recent activities.
This report is available with a Single User License, a Department License (2-10 users) and a Corporate License (11+ users). View the License here. Select the appropriate License in the drop-down menu.
Pharmacy benefit managers (PBMs) play a major role in the provision of pharmacy services by acting as intermediaries between pharmacies, plan sponsors (insurance companies and employers), pharmaceutical manufacturers, and drug wholesalers.
The market for PBM services is highly concentrated, with the top three firms (CVS Health/Caremark, Cigna (Evernorth/Express Scripts, and UnitedHealth (OptumRx) controlling an estimated nearly 80% of the market.
PBMs can influence a significant portion of the cost of drugs. Lack of price transparency for employers in many PBM contracts have led many stakeholders to question how they function, what deals they make, how they generate revenue, and what specific services they perform.
As the role of and visibility have increased, PBMs have come under increased scrutiny from policy makers for their role in drug pricing discussions.
Pharmacy benefit managers are also encountering competition from new pharmacy players, such as Mark Cuban Cost Plus Drugs, and a number of other companies that AMI profiles as non-traditional market participants in the report.
Many of these companies are promoting transparency in their pricing models in which they pass 100% of the discounts they receive from pharmacies and pharmaceutical companies to the health plan/employer sponsor.
The 2024-2025 PBM Review (210 pages) offers comprehensive intelligence on nearly 70 PBM companies. The report identifies and segments the market into Market Leaders, Mid-Market PBMs, and Non-Traditional PBMs. AMI’s complementary report, PBM Platform Companies 2024-2025 Review, will be published in June 2024.
Each PBM company profile includes: company background, strategy, key decision-makers, financial/investor information, products and services, and recent activities.
AMI continues to monitor and report on the pharmaceutical benefit management market on a continuing basis and works with clients on a custom research basis to provide the market intelligence they need to be successful.
| License | Corporate License, Department License, Single User |
|---|
Market Access & Distribution
Market Access & Distribution
Provider Intelligence
Market Access & Distribution